Supplementary Methods
Ethics approval and consent to participate: Discovery study. Institutional review boards and ethics committees at each participating centre approved the study. All participants provided written 35-years-old and reported having symptoms of idiopathic interstitial pneumonia for at least 3 months. A high-resolution CT scan that showed definite or probable usual interstitial pneumonitis was necessary for inclusion. A surgical lung biopsy sample to confirm usual interstitial pneumonitis could be obtained if the diagnosis was in doubt. Patients with clinically significant exposure to known fibrogenic agents and those with other known causes of interstitial lung disease were excluded before study entry.
Ethics approval and consent to participate: Replication study. The IPF cases and UK Biobank controls used for replication have been previously described [1] . In brief, the IPF cases were 
Sequencing of the regions-of-interest (ROIs).
Genomic DNA (gDNA) was extracted from peripheral blood and the integrity and quantity were assessed. All library preparation reagents were purchased from Agilent Technologies and performed at the Research Resources Centre of University of Illinois at Chicago (Chicago, IL). gDNA was sheared to ~200 bp using Covaris S-220 (Covaris Inc.), and size distribution confirmed by TapeStation analysis. Sequencing (>100X) was performed using the SureSelect™ Target Enrichment System XT2 kit ILM with a customdesigned capture of 1.7 Mb (Table S1) NGS data processing, variant calling and annotation. SeqPrep 0.4 was used to remove sequence adaptors and merge overlapping reads. NovoAlign 3.02.00 (Novocraft Technologies Sdn Bhd, Malaysia) was used for read-mapping to the hg19 human genome. Picard 1.7 and SAMtools 0.1.18 [2] were used for BAM file manipulation and to mark duplicates. Qualimap 2.1 [3] indicated that >98% of genomic locations within ROIs were covered at a minimum depth of 90X. GATK 3.3 [4] was used for joint genotyping of small indels and SNVs identified with the HaplotypeCaller following the best practices workflow recommendations. GATK was also used to calculate the transition-to-transversion (Ti/Tv) ratio using the 1000 Genomes Project data (1KGP) as a reference. A false discovery rate (FDR) was calculated to estimate the proportion of false variants declared, assuming a Ti/Tv of 2.25 according to previous whole genome sequencing data [5] . Since the samples were previously genotyped with the Genome-Wide Human SNP Array 6.0 (Affymetrix Inc.) [6] , we also evaluated genotyping concordance between array and NGS data.
Finally, variant annotation was conducted with ANNOVAR [7] and snpEff4_1h [8] based on data from different sources including the NHLBI Grand Opportunity Exome Sequencing Project, 1KGP, Complete Genomics, COSMIC, dbSNP, and PolyPhen predictions. This information was further supplemented with empirical data generated by the ENCODE project [9] as reported by HaploReg v4.1 [10] and RegulomeDB [11] . Conserved regions that exhibit evidence of selective constraint were also scored by GERP [12] and SiPhy [13] .
Validation of low-frequency variants. DNA samples from carriers of the significantly associated rare variants were subjected to direct Sanger sequencing for validation purposes. To overcome the difficulties of the low-complexity sequences within the targeted regions, we used two sets of primer pairs to target the variants in each region: one pair for the amplification step (boost primers) that followed standard PCR protocols, and another pair for sequencing (nested primers), which were used for sequencing both strands of the amplicon to ensure optimal sequencing results.
Sequencing was performed by Eurofins Genomics (Louisville, KY) and the resulting traces were manually revised using 4Peaks v1.8 (Nucleobytes). A list of the primer pairs utilized is provided in Table S2 .
Replication study. Around 800,000 variants were genotyped in these samples and subjected to strict quality controls. The cases and one third of the controls were genotyped using the Affymetrix Axiom UK BiLEVE array (Affymetrix). The rest of controls were genotyped using the Affymetrix Axiom UK Biobank array (Affymetrix). Phasing and imputation were performed with SHAPEIT v2 [14] and IMPUTE2 v2.3.2 [15] , using 1KGP Phase 3 and UK10K as reference panels.
Association testing was conducted assuming an additive genetic effect, considering age, sex and the first 10 PCs as covariates. Additional genotyping, imputation and association study details have been described elsewhere [1] . 
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